Cardiovascular Disease

Heating Up: Two Heart Medications May Increase Risk

hot

Antiplatelet medications and beta blockers can improve survival and quality of life for people with cardiovascular disease. But those protections may come with added risk on hot summer days.

A study published in Science found that a disproportionate number of people who suffer non-fatal heart attacks during hot weather are taking antiplatelet or beta blocker medications. 

Researchers analyzed 2.5k cases in which a non-fatal heart attack occurred during hot weather. Heat-associated MI events were more common among those taking the heart drugs:

  • Antiplatelet medication users had a 63% increased risk.
  • Beta-blocker users had a 65% increased risk.
  • People taking both drugs had a 75% higher risk.
  • Non-users were not more likely to have a heart attack on hot days. 

Importantly, the authors do not claim that these medications cause heart attacks, noting that patients who take these prescriptions are likely doing so because they are more susceptible to cardiac events.  

Even so, a clue indicates that the heart drugs may indeed be partly to blame. Younger patients (25 to 59 years) had lower rates of coronary heart disease than older participants (60 to 74 years), yet younger patients taking beta-blockers and antiplatelet medications were still more susceptible to heat-related heart attacks.

The authors speculate that the medications may make it harder for people to regulate their body temperature, but future research will be necessary to investigate this. 

The Takeaway

Two groups of heart medications – beta blockers and antiplatelets – could potentially place patients at a higher risk of heat-related heart attacks. As temperatures continue to creep up globally, the risk associated with these medications may become even more pronounced. 

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiac Imaging June 16, 2025

Beyond Hardware: Is AI the Answer to Making Cardiac Imaging more Accessible? June 16, 2025

Sponsored by Philips Healthcare Cardiac imaging has traditionally improved through hardware advances, enabling the speed needed for high-quality images. However, hardware is rapidly reaching its physical limitations in suppressing cardiac motion and represents a large financial investment. Today, software and AI are driving the next leap in cardiac image quality and motion control – offering […]

Cardiology Pharmaceuticals June 12, 2025

FDA Approves a New BP Triple Polypill June 12, 2025

Bringing a more effective BP therapy to the U.S. market, the FDA approved George Medicines’ triple therapy polypill called Widaplik for patients with hypertension, making it the first of its kind to go to market in the U.S. Widaplik’s approval stems from two studies, including one comparing the polypill against placebo as an initial treatment […]

Cardiology Pharmaceuticals June 12, 2025

Pharmacologic Preconditioning to Improve Outcomes in Patients Undergoing Cardiac Surgery  June 12, 2025

The majority of patients undergoing cardiac surgery, especially those on cardiopulmonary bypass (CPB), experience post-operative complications such as new-onset atrial fibrillation (POAF) and acute kidney injury (AKI), largely driven by oxidative stress and inflammation.   Several approaches have been explored to reduce complications following cardiac surgery, however, a clinically meaningful impact has yet to be realized.  […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!